Tags: Lilly | drugs | generics | competition

Lilly Beats Forecast, Helped by Drugs Soon to Face Generics

Wednesday, 24 Jul 2013 06:50 AM

Eli Lilly and Co. reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales growth of depression and impotence treatments that will soon lose patent protection, and the drugmaker raised its full-year profit forecast.

Lilly on Wednesday said it earned $1.21 billion, or $1.11 per share in the second quarter. That compared with $924 million, or 83 cents per share, a year earlier.

Excluding special items, Lilly earned $1.16 per share. Analysts on average had forecast $1 per share, according to Thomson Reuters I/B/E/S.

 

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Eli Lilly and Co. reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales growth of depression and impotence treatments that will soon lose patent protection, and the drugmaker raised its full-year profit forecast.
Lilly,drugs,generics,competition
85
2013-50-24
Wednesday, 24 Jul 2013 06:50 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved